Compare Charles River Laboratories Intl. Inc (CRL) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Western Alliance Bancorporation — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while Western Alliance Bancorporation trades at $81.98 (market cap $8.77B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Western Alliance Bancorporation pays a 2.09% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | WAL | |
|---|---|---|
Market Cap | $11.14B | $8.77B |
Sector | Health | Financials |
52-Week High | $233.60 | $96.08 |
52-Week Low | $145.57 | $66.70 |
Enterprise Value | $14.00B | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Western Alliance Bancorporation (WAL) trades at $80.49, down 0.25% on the day, with a bearish technical signal and mixed fundamentals. The stock shows strong analyst support with a consensus price target of $90.67 and 79% buy ratings, but recent earnings beats are overshadowed by negative operating cash flow and high interest expenses. Recent news highlights strategic lending growth and industry recognition, including a #1 bank ranking in Arizona by Forbes in June 2026.
The outlook is cautiously optimistic given Wall Street's bullish stance and valuation discounts, but risks include cash flow pressures and macroeconomic sensitivity. Upside hinges on execution of lending growth and margin improvement, while downside could stem from credit quality deterioration or rising rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
